This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Salesforce, HP, Snowflake All Down on Reported Earnings
by Mark Vickery
Shares of Snowflake (SNOW) have fallen precipitously, nearly -25%, on the news that its CEO, Frank Slootman, would retire after 5 years on the job.
Here's What Key Metrics Tell Us About Salesforce.com (CRM) Q4 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Salesforce.com (CRM) give a sense of how the business performed in the quarter ended January 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Salesforce.com (CRM) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Salesforce.com (CRM) delivered earnings and revenue surprises of 1.33% and 0.81%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?
Q4 GDP and Consumption Revisions
by Zacks Equity Research
Q4 GDP and Consumption Revisions
Q4 GDP, Trade Deficit Both Dip; TJX Beats in Q4
by Mark Vickery
The first revision to Q4 GDP came in 10 bps light of estimates and the previous print.
The Zacks Analyst Blog Highlights JPMorgan Chase, Salesforce, Vertex Pharmaceuticals, Palo Alto Networks and The Williams Companies
by Zacks Equity Research
JPMorgan Chase, Salesforce, Vertex Pharmaceuticals, Palo Alto Networks and The Williams Companies are part of the Zacks top Analyst Blog.
This Week's 5 Red-Hot Earnings Charts
by Tracey Ryniec
These stocks are breaking out and have great earnings surprise track records. Will they beat again?
Top Stock Reports for JPMorgan Chase, Salesforce & Vertex Pharmaceuticals
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Salesforce, Inc. (CRM) and Vertex Pharmaceuticals Incorporated (VRTX).
Wall Street Awaits PCE/Core PCE Data
by Zacks Equity Research
Wall Street Awaits PCE/Core PCE Data
Pre-Markets Up to Start a New Trading Week
by Mark Vickery
The all-important Personal Consumption Expenditures (PCE) on Thursday will take center stage, as it is the Fed's favored metric for tracking inflation.
Rapid Cloud Migration to Aid Salesforce's (CRM) Q4 Earnings
by Zacks Equity Research
Cloud migration and digital transformation initiatives adopted by enterprises despite ongoing macroeconomic headwinds are likely to have aided Salesforce's (CRM) revenues and earnings in Q4.
Pre-Markets Still up on Last Session's Rally
by Zacks Equity Research
Pre-Markets Still up on Last Session's Rally.
Pre-Markets Look to Close Trading Week Higher
by Mark Vickery
We're at monthly and year-to-date highs on all but the small-cap Russell 2000.
Is Salesforce.com (CRM) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Salesforce.com (CRM) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
What Analyst Projections for Key Metrics Reveal About Salesforce.com (CRM) Q4 Earnings
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Salesforce.com (CRM), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended January 2024.
Salesforce (CRM) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
While the growing adoption of generative AI-enabled solutions and the continued cloud migration are likely to have aided Salesforce's (CRM) revenues in Q4, cost-cutting initiatives are anticipated to have boosted profitability.
Is Salesforce Stock a Buy Ahead of Q4 Earnings as Tech Stocks Soar?
by Benjamin Rains
The cloud software firm has also outperformed tech over the last decade and the past 12 months. The question for investors is whether they should consider buying Salesforce shares right now.
Time to Buy These Highly-Ranked Computer Software Stocks
by Shaun Pruitt
Several computer software stocks currently hold spots on the Zacks Rank #1 (Strong Buy) list and here are three to consider.
Salesforce.com (CRM) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
Salesforce.com (CRM) closed at $286.39 in the latest trading session, marking a -1.15% move from the prior day.
Here is What to Know Beyond Why Salesforce Inc. (CRM) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Salesforce.com (CRM) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Invest in the First Trust Dow Jones Internet ETF (FDN)?
by Zacks Equity Research
Sector ETF report for FDN
Salesforce.com (CRM) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Salesforce.com (CRM) closed at $287.32 in the latest trading session, marking a -1.37% move from the prior day.
Is Trending Stock Salesforce Inc. (CRM) a Buy Now?
by Zacks Equity Research
Salesforce.com (CRM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Brokers Suggest Investing in Salesforce.com (CRM): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Salesforce.com (CRM) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Salesforce.com (CRM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
The latest trading day saw Salesforce.com (CRM) settling at $288.11, representing a +0.86% change from its previous close.